|
Apr 8
|
FDA Expands J&J's (JNJ) Carvykti Label in Multiple Myeloma
|
|
Apr 8
|
J&J's (JNJ) $13.1B Shockwave Deal to Boost MedTech Cardio
|
|
Apr 8
|
2 Dividend Stocks to Buy and Hold Forever
|
|
Apr 7
|
Here's the $4.7 Trillion Market Nvidia Has Its Eyes on Now
|
|
Apr 6
|
Can a New CEO Fix Boeing?
|
|
Apr 6
|
CARVYKTI® is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy
|
|
Apr 5
|
Johnson & Johnson Ends The Shockwave Rumor Mill With $13.1 Billion Takeover
|
|
Apr 5
|
Johnson & Johnson to Buy Shockwave Medical in $13.1 Billion Deal
|
|
Apr 5
|
Acquisition Watch: Time to Buy Johnson & Johnson (JNJ) or ShockWave Medical's (SWAV) Stock?
|
|
Apr 5
|
Stocks Soar After Robust Jobs Data; AMD, Amazon.com Lead Tech Rally, But Tesla Sinks On This News
|
|
Apr 5
|
Market Rally Under Pressure; Tesla, Humana In Focus: Weekly Review
|
|
Apr 5
|
Johnson & Johnson to Buy Shockwave Medical for $13.1 Billion. It’s a Cardio Health Play.
|
|
Apr 5
|
J&J to pump another $13B into its MedTech business with Shockwave deal
|
|
Apr 5
|
Institutional owners may consider drastic measures as Johnson & Johnson's (NYSE:JNJ) recent US$14b drop adds to long-term losses
|
|
Apr 5
|
UPDATE 5-J&J boosts heart device business in $13.1 bln Shockwave deal
|
|
Apr 5
|
J&J boosts heart device business in $13.1 billion Shockwave deal
|
|
Apr 5
|
Johnson & Johnson to Acquire Shockwave Medical
|
|
Apr 5
|
J&J to acquire Shockwave Medical for $13.1B
|
|
Apr 4
|
Johnson & Johnson Recommends Shareholders Reject "Mini-Tender" Offer by TRC Capital Investment Corporation
|
|
Apr 4
|
FDA approves new antibiotic for several hard-to-treat infections
|